<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736914</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-2002-IIT</org_study_id>
    <nct_id>NCT04736914</nct_id>
  </id_info>
  <brief_title>Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma</brief_title>
  <official_title>A Perspective Study of Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma (BRIDGE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, single-arm, phase II study of Zanubrutinib-based&#xD;
      induction followed by ASCT and Zanubrutinib maintenance (2 years) or followed directly by&#xD;
      Zanubrutinib maintenance without ASCT in young and fit patients with untreated MCL.&#xD;
&#xD;
      There will be an initial safety run-in phase of 6 patients which will be closely monitored&#xD;
      for the observed toxicities during cycle1 in， induction therapy. After completion of safety&#xD;
      run-in phase, the investigator will assessed and decided whether to continue the trial as&#xD;
      planned. If no unexpected toxicity has been observed, study will expand the sample size to&#xD;
      further assess efficacy and safety.&#xD;
&#xD;
      Total around 47 patients aged 18-65 years with previously untreated, Ann Arbor stage II-IV,&#xD;
      histologically proven MCL will be enrolled to receive alternating 3 cycles R-CHOP +&#xD;
      Zanubrutinib /3 cycles R-DHAOx induction. Totally 6 cycles in induction and every 21 days per&#xD;
      cycle. Due to lack of published data about BTKi in combination with R-DHAOx, Zanubrutinib is&#xD;
      only applied in cycle 1,3,5(R-CHOP), 160mg BID, d1-21, and not in combination with R-DHAOx&#xD;
&#xD;
      Patients who achieve remission (≥PR) will be allowed to proceed to ASCT or maintenance.&#xD;
      Whether ASCT or not depends on investigator's evaluation and discretion. In patients who do&#xD;
      not achieve a remission at end of induction (treatment failure), no study specific treatment&#xD;
      is defined; rather, the further salvage treatment is upon the discretion of investigators.&#xD;
      Patients remain in study for progression and survival follow-up.&#xD;
&#xD;
      Patients will receive Zanubrutinib maintenance for two years in case of remission at ASCT&#xD;
      assessment or end of induction assessment. Zanubrutinib is applied oral 160mg BID,&#xD;
      continuously for 2 year or until progressive disease, unacceptable toxicity or death,&#xD;
      whichever comes first.&#xD;
&#xD;
      The primary analysis will be performed after last-patient completes induction treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Zanubrutinib Combined with R-CHOP，R-DHAOx</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRD negativity rate</measure>
    <time_frame>18 weeks</time_frame>
    <description>To evaluate the MRD negativity rate after Zanubrutinib-based induction therapy in subjects with newly diagnosed, young and fit MCL.&#xD;
The primary endpoint of the trial will be bone marrow minimal residual disease (MRD) negative rate after induction therapy (at the completion of cycle 6 or at premature discontinuation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of MRD negativity</measure>
    <time_frame>60 months</time_frame>
    <description>The time from the first achieving MRD negativity after start of treatment to the MRD convert to positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>60 months</time_frame>
    <description>The time from start of treatment to progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>60 months</time_frame>
    <description>The time from start of treatment to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Zanubrutinib+R-CHOP/R-DHAOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction:&#xD;
Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:&#xD;
ASCT conditioning&#xD;
Maintenance:&#xD;
Zanubrutinib, 160mg PO BID, continuously for 2 year&#xD;
Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT&#xD;
Requirements for start of maintenance:&#xD;
ANC ≥ 1,000 cells/mm³ (1.0 X 109/L);&#xD;
Platelets ≥ 50,000 cells/mm³ (50 X 109/L);</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）</intervention_name>
    <description>Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:&#xD;
R-CHOP (cycle 1,3,5):&#xD;
Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral&#xD;
R-DHAOx (cycle 2,4,6):&#xD;
Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.&#xD;
Maintenance:&#xD;
Zanubrutinib, 160mg PO BID, continuously for 2 year or until progressive disease。&#xD;
Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT</description>
    <arm_group_label>Zanubrutinib+R-CHOP/R-DHAOx</arm_group_label>
    <other_name>R-CHOP，R-DHAOx，Brukinsa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 1. Histologically confirmed diagnosis of MCL according to WHO classification&#xD;
&#xD;
          2. Previously untreated MCL&#xD;
&#xD;
          3. Suitable for high-dose treatment including high-dose Ara-C&#xD;
&#xD;
          4. Age ≥ 18 years and ≤ 65 years&#xD;
&#xD;
          5. Stage II-IV (Ann Arbor)&#xD;
&#xD;
          6. Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI).&#xD;
             Measurable disease was defined as at least 1 lymph node &gt; 1.5 cm in longest diameter&#xD;
             and measurable in 2 perpendicular dimensions; in case of bone marrow infiltration&#xD;
             only, bone marrow aspiration and biopsy are mandatory for all staging evaluations&#xD;
&#xD;
          7. ECOG performance status ≤ 2&#xD;
&#xD;
          8. The following laboratory values at screening (unless related to MCL):&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1×10⁹/L&#xD;
&#xD;
               -  Platelets ≥ 75×10⁹/L (platelets ≥ 50×10⁹/L with bone marrow involvement)&#xD;
&#xD;
               -  Transaminases (AST and ALT) ≤ 3 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin ≤ 2 × ULN (unless documented Gilbert's syndrome)&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          9. International normalized ratio ≤ 1.5 and activated partial thromboplastin time ≤ 1.5 x&#xD;
             upper limit of normal. If a factor inhibitor was present with prolongation of the&#xD;
             international normalized ratio or activated partial thromboplastin time.&#xD;
&#xD;
         10. Sexually active men and women of child-bearing potential must agree to use highly&#xD;
             effective contraceptives (eg, condoms, implants, injectables, combined oral&#xD;
             contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while&#xD;
             on study; this should be maintained for 90 days after the last dose of study drug&#xD;
&#xD;
         11. Life expectancy of&gt; 3 months&#xD;
&#xD;
         12. Written informed consent form according to GCP and national regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known CNS involvement of MCL&#xD;
&#xD;
          2. Major surgery within 4 weeks of screening&#xD;
&#xD;
          3. Prior hematopoietic stem cell transplantation&#xD;
&#xD;
          4. Concomitant or previous malignancies within the last 2 years other than basal cell&#xD;
             skin cancer or in situ uterine cervix cancer&#xD;
&#xD;
          5. Clinically significant cardiovascular disease such as uncontrolled arrhythmias and&#xD;
             hypertension , congestive heart failure, or myocardial infarction within 6 months of&#xD;
             Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by&#xD;
             the New York Heart Association Functional Classification or LVEF below 50%（AHA，2016）&#xD;
&#xD;
          6. QTcF &gt; 450 msec or other significant electrocardiogram (ECG) abnormalities including&#xD;
             second-degree atrioventricular block Type II, or third-degree atrioventricular block&#xD;
&#xD;
          7. Clinically significant hypersensitivity (eg, anaphylactic or anaphylactoid reactions&#xD;
             to the compound of zanubrutinib itself or to the excipients in its formulation)&#xD;
&#xD;
          8. Requires treatment with strong CYP3A inhibitors or strong CYP3A inducers&#xD;
&#xD;
          9. Unable to swallow capsules or disease significantly affecting gastrointestinal&#xD;
             function such as malabsorption syndrome, resection of the stomach or small bowel,&#xD;
             bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or&#xD;
             complete bowel obstruction&#xD;
&#xD;
         10. Patients with unresolved hepatitis B or C infection or known HIV positive infection&#xD;
&#xD;
         11. Active infection including infections requiring oral or intravenous antimicrobial&#xD;
             therapy&#xD;
&#xD;
         12. Any life-threatening illness, medical condition, or organ system dysfunction that, in&#xD;
             the investigator's opinion, could have compromised the patient's safety, or put the&#xD;
             study at risk&#xD;
&#xD;
         13. History of stroke or intracranial hemorrhage within 6 months before first dose of&#xD;
             study drug&#xD;
&#xD;
         14. Pregnancy or lactation&#xD;
&#xD;
         15. Participation in another clinical trial within 30 days before enrollment in this study&#xD;
&#xD;
         16. poor compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>huang huiqiang</last_name>
    <phone>138 0888 5154</phone>
    <email>haunghq@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Oncology, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiqiang Huang, Professor</last_name>
      <phone>+86 020 87343350</phone>
      <email>huanghq@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Huiqiang Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huiqiang Huang</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

